Ozisik Y - Search Results

1

Secondary hematological malignancies after treatment of non-metastatic breast cancer.

Arslan C, Ozdemir E, Dogan E, Ozisik Y, Altundag K. Arslan C, et al. Among authors: ozisik y. J BUON. 2011 Oct-Dec;16(4):744-50. J BUON. 2011. PMID: 22331732

2

Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.

Bulut N, Aksoy S, Dizdar O, Dede DS, Arslan C, Dogan E, Gullu I, Ozisik Y, Altundag K. Bulut N, et al. Among authors: ozisik y. Med Oncol. 2011 Dec;28 Suppl 1:S75-9. doi: 10.1007/s12032-010-9715-9. Epub 2010 Oct 21. Med Oncol. 2011. PMID: 20963641

3

A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.

Buyukhatipoglu H, Babacan T, Kertmen N, Balakan O, Suner A, Ates O, Sarici F, Aslan A, Diker O, Tasdemir V, Ozisik Y, Altundag K. Buyukhatipoglu H, et al. Among authors: ozisik y. J BUON. 2015 Jan-Feb;20(1):22-7. J BUON. 2015. PMID: 25778291 Free article.

4

Molecular subtypes in patients with inflammatory breast cancer; a single center experience.

Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akin S, Arik Z, Aslan A, Ates O, Aksoy S, Ozisik Y, Altundag K. Kertmen N, et al. Among authors: ozisik y. J BUON. 2015 Jan-Feb;20(1):35-9. J BUON. 2015. PMID: 25778293 Free article.

5

The effect of obesity on recurrence pattern in early breast cancer patients.

Yazici O, Aksoy S, Sendur MA, Babacan T, Ozdemir N, Ozisik Y, Zengin N, Altundag K. Yazici O, et al. Among authors: ozisik y. J BUON. 2015 Jul-Aug;20(4):954-62. J BUON. 2015. PMID: 26416043 Free article.

6

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K. Ates O, et al. Among authors: ozisik y. J BUON. 2016 Mar-Apr;21(2):375-81. J BUON. 2016. PMID: 27273947 Free article.

7

Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients.

Ozen M, Gunduz M, Ates O, Babacan T, Sever AR, Akin S, Ozisik Y, Altundag K. Ozen M, et al. Among authors: ozisik y. J BUON. 2016 Jul-Aug;21(4):799-808. J BUON. 2016. PMID: 27685899 Free article.

8

Pure mucinous carcinoma of the breast: a single center experience.

Dogan E, Aksoy S, Dizdar O, Arslan C, Dede DS, Ozisik Y, Altundag K. Dogan E, et al. Among authors: ozisik y. J BUON. 2011 Jul-Sep;16(3):565-7. J BUON. 2011. PMID: 22006768

9

Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single institution experience from Turkey.

Turkoz FP, Solak M, Aksoy S, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Simsek E, Ozisik Y, Altundag K. Turkoz FP, et al. Among authors: ozisik y. J BUON. 2012 Oct-Dec;17(4):649-57. J BUON. 2012. PMID: 23335520

10

Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.

Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Dede DS, et al. Among authors: ozisik y. J BUON. 2013 Jan-Mar;18(1):57-63. J BUON. 2013. PMID: 23613389 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters